浙江昂利康制药股份有限公司关于获得药品注册证书的公告

Core Viewpoint - Zhejiang Anglikang Pharmaceutical Co., Ltd. has received the drug registration certificate for Levofloxacin Tablets from the National Medical Products Administration, which is expected to enhance the company's product pipeline and market presence [1][2]. Group 1: Drug Information - Levofloxacin Tablets are the left-handed optical isomer of Ofloxacin, classified as a third-generation fluoroquinolone antibiotic, known for its broad antibacterial spectrum and strong antibacterial action [1]. - The drug is indicated for the treatment of moderate to severe infections in adults (≥18 years) caused by specified sensitive strains, including hospital-acquired pneumonia, community-acquired pneumonia, acute bacterial sinusitis, acute exacerbations of chronic bronchitis, complex skin and skin structure infections, uncomplicated skin and soft tissue infections, and chronic bacterial prostatitis [1]. Group 2: Impact on the Company - The approval of Levofloxacin Tablets will further enrich the company's product pipeline, potentially leading to increased market opportunities [2]. - However, the sales of pharmaceuticals are subject to uncertainties due to the unique nature of the industry, influenced by national policies and market environment changes [2].